Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AKESOgen and London Genetics International have entered into a strategic alliance to enhance drug development through pharmacogenetics and related services.
Subscribe to our email newsletter
The financial terms of the agreement have not been disclosed.
AKESOgen and London Genetics will collaborate to provide pharmacogenetic solutions, such as novel biomarker and assay development services for biopharma companies.
The companies, through the alliance, can help customers access additional resources and speed the delivery of targeted treatments.
London Genetics personalised medicine and nutrition VP Elizabeth Foot said the compay’s expertise in pharmacogenetic strategy development combined with a professional genomics services company that operates to CLIA standards will make this strategic alliance beneficial to both companies.
"This represents our first deal following our acquisition by LSBC which from our side was a critical step for making this happen," Foot added.